Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AD 201

Next Previous
Drug Profile

AD 201

Alternative Names: AD-201

Latest Information Update: 18 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Addpharma
  • Class Antihyperlipidaemics; Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Hyperlipidaemia; Hypertension

Most Recent Events

  • 30 Sep 2021 Preregistration for Hyperlipidaemia in South Korea (PO)prior to September 2021 (Addpharma pipeline, August 2022).
  • 30 Sep 2021 Preregistration for Hypertension in South Korea (PO) prior to September 2021 (Addpharma pipeline, August 2022).
  • 30 Sep 2021 Registered for Hyperlipidaemia in South Korea (PO) in September 2021 - First global approval (Addpharma pipeline, August 2022).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top